Navigation Links
Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
Date:8/31/2007

EMERYVILLE, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), announced today that on August 29, 2007, the Company received notification from the NASDAQ Listing Qualifications Department that it is not in compliance with the $35 million market value of listed securities requirement for continued listing on The NASDAQ Capital Market set forth in NASDAQ Marketplace Rule 4310(c)(3)(B). In accordance with Marketplace Rule 4310(c)(8)(C), the Company has a cure period of 30 calendar days, or until September 28, 2007, to regain compliance.

The Company was further advised that it does not comply with either the NASDAQ's minimum $2.5 million stockholders' equity requirement set forth in Marketplace Rule 4310(c)(3)(A) or the requirement under Marketplace Rule 4310(c)(3)(C) that the Company report at least $500,000 net income from continuing operations in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. To maintain its listing, the Company must comply with at least one of these three alternative listing standards.

The Company expects that it will be able to regain compliance under Marketplace Rule 4310(c)(3)(B) through its proposed public offering of up to $65 million of its common stock, pursuant to the registration statement on Form S-1 that was filed with the SEC on August 13, 2007 and which is expected to close after the above-referenced 30-day cure period expires on September 28, 2007.

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Baltimore, MD (PRWEB) , ... September 20, 2017 ... ... for digital pathology, and Huron Digital Pathology , a provider of whole ... Association’s 2017 Pathology Visions conference . The workshop, entitled “Successfully Deploying a Best-in-Class ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... From industry ... therapy succeeded after standard medicine failed. Many of these people had lost all hope. ... Regression Free Download (pdf) , “Neil takes readers on ...
(Date:9/20/2017)... ... September 20, 2017 , ... RoviSys, a leading independent ... the opening of an office in Taipei, Taiwan. This new location allows RoviSys ... developing new relationships in the region. Located in the Neihu area of Taipei, ...
(Date:9/19/2017)... ... 19, 2017 , ... Participants of this educational webinar will ... Along with the advantages and disadvantages of ductless, filtered fume hoods, they will ... laboratory. , Attendees will learn from an industry expert about the different types ...
Breaking Biology Technology:
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):